

Complete Listing of the Claims

This listing of claims will replace all prior versions, and listings of claims in the application.

1 - 16. (Canceled)

17. (Currently amended) An antisense oligonucleotide which is complementary to an NTP mRNA sequence corresponding to nucleotides 150-1139 of ~~Seq. ID No. 1~~ SEQ ID NO:1.

18. (Original) The antisense oligonucleotide of claim 17, which is a 15 to 40-mer.

19. (Currently amended) The antisense oligonucleotide of claim 17, wherein said antisense oligonucleotide is selected from the group consisting of ~~Seq ID Nos. 9 to 11~~ SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11.

20. (Original) The antisense oligonucleotide of claim 17, which is deoxyribonucleic acid.

21. (Original) The antisense oligonucleotide of claim 17, which is deoxyribonucleic acid phosphorothioate.

22. (Original) The antisense oligonucleotide of claim 17, which is a derivative of a deoxyribonucleic acid or a deoxyribonucleic acid phosphorothioate.

23. (Original) A pharmaceutical composition comprising the antisense oligonucleotide of claim 17 and a pharmaceutically acceptable carrier.

24. (Currently amended) A ribozyme comprising a target sequence which is complementary to an NTP mRNA sequence corresponding to nucleotides 150-1139 of ~~Seq. ID No. 1~~ SEQ ID NO:1.

25. (Original) A pharmaceutical composition comprising the ribozyme of claim 24 and a pharmaceutically acceptable carrier.

26. (Currently amended) An oligodeoxynucleotide that forms one or more triple stranded regions with the a coding region of AD7c-NTP ~~coding nucleic acid and having DNA, wherein said oligodeoxynucleotide has~~ the sequence 3'X5'-L-5'X3', wherein X comprises an AD7c-NTP nucleic acid sequence corresponding to nucleotides 150-1139 of ~~Seq. ID No. 1~~ SEQ ID NO:1, and wherein L represents an oligonucleotide linker or a bond.

27. (Original) A pharmaceutical composition comprising the oligodeoxynucleotide of claim 26 and a pharmaceutically acceptable carrier.

28. (Currently amended) An oligodeoxynucleotide that forms one or more triple stranded regions with the a coding region of AD7c-NTP ~~coding nucleic acid and having DNA, wherein said oligodeoxynucleotide has~~ the sequence 5'X3'-L-3'X5', wherein X comprises an AD7c-NTP nucleic acid sequence corresponding to nucleotides 150-1139 of ~~Seq. ID No. 1~~ SEQ ID NO:1, and wherein L represents an oligonucleotide linker or a bond.

29. (Original) A pharmaceutical composition comprising the oligodeoxynucleotide of claim 28 and a pharmaceutically acceptable carrier.

30. (Currently amended) A ribonucleotide external guide nucleic acid molecule, comprising[,] a 10-mer nucleotide sequence corresponding to nucleotides 150-1139 of ~~Seq. ID No. 1~~ SEQ ID NO:1 fused to a 3'NCCA nucleotide sequence, wherein N is a purine.

31. (Currently amended) The ribonucleotide external guide nucleic acid molecule of claim 30 which is selected from the group consisting of ~~any one of Seq. ID Nos. 12 to 14~~ SEQ ID NO:12, SEQ ID NO:13 and SEQ ID NO:14.

32. (Original) A pharmaceutical composition comprising the ribonucleotide of claim 30 and a pharmaceutically acceptable carrier.

33 - 34. (Canceled)